Emcure Cuts Price by 47% to Boost Access to Weight Loss Drug Poviztra

Emcure Pharmaceuticals has sharply cut the price of its weight-loss drug Poviztra across India, slashing costs by an average of 47% to make the semaglutide-based treatment more affordable for patients.

The reduced pricing takes effect from April 3, 2026, with the lowest dose now at Rs 3,999 per month, down from around Rs 8,790 earlier, and higher doses reduced to as low as Rs 8,999.

This dramatic revision covers all five strengths of the once-weekly injection, aiming to widen access amid rising obesity rates nationwide.

The move comes as competition in the GLP-1 market intensifies following the expiry of semaglutide patents in India, triggering a wave of generic launches and prompting pricing pressure across the segment.

Also Read: Pharma CDMOs in India & CDMO 2.0 Model: Detailed Review 2026

Emcure markets Poviztra as a second brand of Novo Nordisk’s semaglutide injection for chronic weight management, delivered through a once-weekly pen device in strengths from 0.25 mg up to a 2.4 mg maintenance dose.

In an official statement, Emcure said the pricing revision is designed to expand patient access to a proven weight-management therapy at a time when obesity and related conditions are a growing public health concern. The company highlighted that lower prices could help more people benefit from the global clinical evidence supporting semaglutide’s effectiveness.

Industry analysts say the price cut also positions Emcure more competitively against both generic semaglutide products and recent price adjustments by innovator brands. With cost now a key factor for long-term treatment adherence, the revised pricing could reshape how obesity therapies are accessed in India.

Satish Mehta, CEO and Managing Director of Emcure, noted that the move underlines the company’s commitment to improving health outcomes by reducing barriers to scientifically backed weight-loss treatment.

With generics entering the market and legacy prices dropping, India’s weight-loss drug landscape is shifting fast, and Emcure’s Poviztra price cut is a major development in that trend.